Summary: Glanzmann Thrombasthenia (GT) is a congenital thrombopathy characterised by bleeding manifestations that are sometimes severe. Treatment is based on platelet transfusions during bleeding. We report a case of TG revealed by haematuria and which presented a severe bleeding syndrome refractory to transfusions. Treatment with injections of recombinant activated factor VII was necessary. This case illustrates the value of using recombinant activated factor VII in TG in case of antiplatelet alloimmunisation or in case of lack of response to platelet transfusions.

Introduction: Androgen deprivation therapy is the mainstay of systemic treatment for metastatic prostate. However, the majority of patients progress to CRPC. The aim of this study is to identify factors that predict castration resistance in men with locally advanced or metastatic prostate cancer treated with first line ADT. Methods: This is a retrospective and analytical study including 46 patients treated for advanced or metastatic prostate cancer with first-line ADT at the Military Hospital Mohammed 5 of Rabat (HMMV) between November 2013 and July 2018 (a period of 5 years). The elements analyzed were sociodemographic, clinical, patient history, biological and radiological data. Results: Predictive factors for castration resistance in our sample are: 1) A high-risk stage according to the LATITUDE criteria. 2) High initial PSA. 3) PSA nadir (PSAn) > 1.17 ng/ml. 4) Elevated PAL at diagnosis > 129 IU/L. 5) Short time to reach PSAn ≤ 9 months. Conclusion: The risk factors predictive of early resistance to first-line hormonal therapy in patients with metastatic prostate cancer in our series were similar to those described in the literature. We advocate early treatment with hormonal chemotherapy in any patient with metastatic prostate cancer who has any of the elements identified in our study.

Secondary localization of urothelial carcinoma after cystectomy or total cystoprostatectomy (CPT) on the penis (metastasis) is rare, representing 1 to 8%. Occurring within 18 months of the diagnosis of the primary lesion in about 65% according to the literature. The prognosis is often poor with survival rarely exceeding 20 months. The treatment of cavernous metastases of the penis is multidisciplinary, essentially based on surgery (emasculation or penectomy) and chemotherapy, which provide the best results in terms of overall survival. The authors report a case of metastasis, cavernous location of the penis after cystoprostatectomy in 2016 for high-grade urothelial carcinoma of the bladder, whose anatomy-pathology of the surgical specimen is classified pT3a. The patient underwent emasculation (penectomy plus bilateral total orchiepidymectomy involving the entire scrotum). The authors also discuss the diagnostic, therapeutic and prognostic problems that this secondary location poses.